- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pfizer's Bourla Rebuked by UK's Prescription Medicines Code of Practice Authority (PMCPA) for Misleading Comments on Kids' Vaccines
“There is no doubt in my mind that the benefits, completely, are in favour of” vaccinating youngsters ages 5 to 11 against COVID Albert Bourla claimed in an interview with the BBC on Dec. 2, 2021.
UsForThem, a children's advocacy group in the UK, submitted the letter to the PMCPA, calling Bourla's comments "disgracefully misleading" and "extremely promotional in nature" and provided many examples from the interview.
The letter reads: "We are of the opinion that the tone, content and means of dissemination of this article and the associated video are extremely promotional in nature. The PMCPA’s definition of what constitutes promotion is set out in Clause 1.17 of the Code."
The Telegraph reported Bourla breached several clauses of the Association of the British Pharmaceutical Industry’s (ABPI) code of practice.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
